Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

DOI PDF Web Site 被引用文献6件

書誌事項

公開日
2020-05-27
権利情報
  • https://creativecommons.org/licenses/by/4.0
  • https://creativecommons.org/licenses/by/4.0
DOI
  • 10.1186/s13046-020-01601-2
公開者
Springer Science and Business Media LLC

説明

<jats:title>Abstract</jats:title><jats:p>In a large number of cancer types, treatment selection depends on the presence of specific tumor biomarkers. Due to the dynamic nature of cancer, very often these predictive biomarkers are not uniformly present in all cancer cells. Tumor heterogeneity represents indeed one of the main causes of therapeutic failure, and its decoding remains a major ongoing challenge in the field.</jats:p><jats:p>Liquid biopsy is the sampling and analysis of non-solid biological tissue often through rapid and non-invasive methods, which allows the assessment in real-time of the evolving landscape of cancer. Samples can be obtained from blood and most other bodily fluids. A blood-based liquid biopsy can capture circulating tumor cells and leukocytes, as well as circulating tumor-derived nucleic acids.</jats:p><jats:p>In this review, we discuss the current and possibly future applications of blood-based liquid biopsy in oncology, its advantages and its limitations in clinical practice. We specifically focused on its role as a tool to capture tumor heterogeneity in metastatic cancer patients.</jats:p>

収録刊行物

被引用文献 (6)*注記

もっと見る

問題の指摘

ページトップへ